HeartForce is pleased to announce its latest multi-center study, to occur at the end of March 2021, in Uzbekistan. The research study will take place in coordination with three renowned heart centres, located in Tashkent and Karshi. The study will involve 1500 enrolled patients and will be supervised by the Eurasian Heart Foundation (EAHF), headquartered… Continue reading HeartForce to Commence CardioClin Multicenter Study in Uzbekistan
HeartForce is pleased to present a report of its latest studies and results for identifying patients with coronary artery disease (CAD) using seismocardiography (SCG). The findings of this study tested the performance of HeartForce SCG technology in identifying patients with CAD compared to other methods, including ECG stress test and coronary computed tomography angiography (CCTA).… Continue reading HeartForce CAD Report – Seismocardiography: A Reliable Screening Method to Detect Coronary Artery Disease
HeartForce is proud to have been selected as a top 5 company for “Patient Monitoring” by Bayer and has been invited to participate in the company’s 2020 Cardiovascular Growth Challenge. HeartForce was selected as one of the finalists from who participated in the Bayer AG Deutschland G4A Partnership program. The G4A Partnership Program offers leading… Continue reading HeartForce Selected as Top 5 Company and Reaches Final Stage of G4A Partnerships Program with Bayer
HeartForce has reached the final round of the 2020 Swiss Innovation Challenge. The challenge is both an innovation funding program and competition, organized by the Chamber of Commerce of Baselland, the University of Applied Sciences and Arts Northwestern Switzerland (FHNW) and the Basellandschaftliche Kantonalbank (BLKB). Twenty-five finalists and one winner will be selected from over… Continue reading HeartForce Enters the Final Round Receives an Award Nomination in the 2020 Swiss Innovation Challenge
Heart Force has been accepted as one of the Top 60 participant teams for the 2020 K-Startup Grand Challenge (KSGC) in Korea. HeartForce was selected from over 2600 applicants from 118 countries. The K-Startup Grand Challenge is a Korean government-led initiative that supports talented local and international tech companies and entrepreneurs with the goal of… Continue reading HeartForce Accepted for 2020 Korea Grand Challenge Accelerator
Essential for monitoring cardiac performance is the assessment of cardiac time intervals (CTIs). With the introduction of gyrocardiography (GCG) as a non-invasive technology for cardiac monitoring, HeartForce investigates the accuracy and reproducibility of estimating CTIs from the GCG recordings of 50 adults.
HeartForce receives ‘Gold’ at German Innovation Awards 2020, with the presentation of the world’s first complete heart-screening device for the early detection and prevention of heart disease. As a leader in innovation and honouring both products and solutions that distinguish themselves primarily by their user centricity, the German Innovation Awards recognized the HeartForce Cardio Pro… Continue reading Cardio Pro Achieves Gold Standard
Using a combination of seismocardiogram (SCG) and electrocardiogram (ECG), HeartForce conducts an analysis on the repeatability of systolic time intervals (STIs) in healthy subjects via two experiments.
Using rest and exercise seismocardiography, HeartForce presents a non-invasive methodology in helping to identify coronary artery disease (CAD), and combating the most common cause of death worldwide. Discover how the fast, easy and inexpensive SCG examination compares to more traditional CAD assessments of exercise electrocardiography (ECG), coronary angiography and coronary computed tomography angiography (CCTA).
Heart force attended the Computing in Cardiology Conference 2019, Singapore, Singapore and presented the results of study “Estimation of Cardiac Time Intervals from the Mechanical Activity of the Heart Using Machine Learning.”
In clinical examinations, HeartForce investigated the reliability of cardiac time intervals and beat-to-beat extraction of PCG, ICG and SCG signals in relation to the clinical gold standard of multimodal echocardiography (Doppler, TDI, and M-mode). The three non-invasive methodologies possess the potential to be embedded in wearable devices (ICG, SCG, and PCG), and detect clinically relevant… Continue reading HeartForce Investigates Use of PCG, ICG and SCG in Wearable Devices to Detect Cardiac Time Intervals
To investigate the effects of the coronary artery disease on the morphology of the SCG and GCG waveforms, HeartForce designed and conducted an investigational study in the University Hospital Zürich, Switzerland. One hundred and fifty patients participated in this study, who were suspected of having coronary artery disease and were referred to the hospital for… Continue reading HeartForce Investigational Study – University Hospital of Zürich, Switzerland
To investigate the morphology of the SCG and GCG waveforms, Heart force designed and conducted an investigational study in Simon Fraser University in Vancouver, Canada. One hundred individuals in the 40-85 age range were recruited for this study.
HeartForce Medical Inc. held its annual general meeting on August 31, 2017, electing four new board members. Dr. Kouhyar Tavakolian, Dr. Geoff Houlton, Kay Jessel, and Dr. Erwin Bauer were all elected to the board. Beat Naegeli now serves as the chair and Jennie Choboter is Secretary. Kay Jessel was appointed by the newly-elected board… Continue reading New Board Members Appointed to HeartForce Medical’s Board of Directors
To investigate the estimation of cardiac time intervals in healthy young individuals using the SCG and GCG, Heart force designed and conducted an investigational study in Simon Fraser University in Vancouver, Canada. For this study, 120 individuals in the 18-40 age range were recruited.
In pursuit of identifying the respiratory phases of SCG cycles, HeartForce presents an efficient, reliable and accurate approach in analyzing seismocardiogram cycles to identify the respiratory phases. Results obtained from the study possess the ability to be employed to enhance the extraction of clinically valuable information.
Designing a delineation algorithm, HeartForce investigates the ability to detect specific fiducial points of the seismocardiogram (SCG) signal with or without using the electrocardiogram (ECG). Analysis of the presented algorithm indicates whether the algorithm can be used for accurate and noninvasive estimation of cardiac time intervals.
New methods of recording cardiac timings come to light, sparking renewed interest and novel applications for these cardiac timings. Systolic time intervals have been used to detect and quantify the directional changes of left ventricular function in the past, with new methods now suggesting other alternatives.
Prior research states that peaks on dorsoventral and sternal SCG correspond to specific cardiac events, leading to the potential of extracting such peaks for various types of monitoring and diagnosis applications. However, annotation of these peaks is not a trivial task. Here, HeartForce investigates an automated method to annotate these peaks by using automatic annotation… Continue reading Automatic Annotation of Seismocardiogram